Skip to main content
. 2023 Dec 27;5(2):100627. doi: 10.1016/j.jtocrr.2023.100627

Table 2.

Prevalence of Oncogenic Drivers by Age

<=50 years old n = 129 (%) >50 years old n = 1923 (%) P-value
Clinically significant alteration 78 (60.5) 1018 (52.9) 0.097
KRAS 37 (28.7) 620 (32.2) 0.402
EGFR 13 (10.1) 168 (8.7) 0.603
BRAF 4 (3.1) 68 (3.5) 0.795
MET exon 14 skipping - 53 (2.8) 0.076
MET amplification 2 (1.6) 24 (1.2) 0.677
HER2 3 (2.3) 32 (1.7) 0.480
Fusions (ALK/ROS1/RET/FGFR) 19 (14.7) 57 (3) <0.001